Ads
related to: yearly infusion osteoporosis reclast injectionbenchmarkguide.com has been visited by 10K+ users in the past month
Search results
Results from the WOW.Com Content Network
Reclast (zoledronic acid or zoledronate) is an infusion to treat osteoporosis. It's typically covered by Original Medicare (parts A and B).
These include osteoporosis, high blood calcium due to cancer, bone breakdown due to cancer, Paget's disease of bone [3] and Duchenne muscular dystrophy (DMD). It is given by injection into a vein. [3] Common side effects include fever, joint pain, high blood pressure, diarrhea, and feeling tired. [3]
Patients being treated for osteoporosis or non-malignant bone disease with oral bisphosphonates/quarterly or yearly infusions of intravenous bisphosphonates for >5 years; Patients being treated for osteoporosis or non-malignant bone disease with bisphosphonates/denosumab for any length of time as well as being treated with systemic glucocorticoids
They are used for the treatment of osteoporosis and other bone disorders that cause bone fragility and diseases where bone resorption is excessive. Osteoporosis is common in post-menopausal women and patients in corticosteroid treatment where biphosphonates have been proven a valuable treatment and also used successfully against Paget's disease ...
In large studies, women taking bisphosphonates for osteoporosis have had unusual fractures ("bisphosphonate fractures") in the femur (thigh bone) in the shaft (diaphysis or sub-trochanteric region) of the bone, rather than at the femoral neck, which is the most common site of fracture. However, these fractures are rare (12 in 14,195 women ...
Ibandronic acid is a bisphosphonate medication used in the prevention and treatment of osteoporosis and metastasis-associated skeletal fractures in people with cancer. [4] It may also be used to treat hypercalcemia (elevated blood calcium levels). It is typically formulated as its sodium salt ibandronate sodium. [medical citation needed]
Twice-yearly shots used to treat AIDS were 100% effective in preventing new infections in women, according to study results published Wednesday. There were no infections in the young women and ...
In June 2010, denosumab was approved by the FDA for use in postmenopausal women with risk of osteoporosis [31] under the brand name Prolia, [32] and in November 2010, as Xgeva for the prevention of skeleton-related events in people with bone metastases from solid tumors. [33] Denosumab is the first RANKL inhibitor to be approved by the FDA. [31]
Ads
related to: yearly infusion osteoporosis reclast injectionbenchmarkguide.com has been visited by 10K+ users in the past month